Compare NMZ & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMZ | TYRA |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2021 |
| Metric | NMZ | TYRA |
|---|---|---|
| Price | $10.42 | $21.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.20 |
| AVG Volume (30 Days) | 356.8K | ★ 579.0K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.26 | $6.42 |
| 52 Week High | $11.14 | $24.05 |
| Indicator | NMZ | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 34.27 | 62.96 |
| Support Level | $10.51 | $21.66 |
| Resistance Level | $10.60 | $24.05 |
| Average True Range (ATR) | 0.08 | 1.30 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 14.81 | 47.17 |
Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The company's investment objectives is to provide current income exempt from regular federal income tax by investing predominantly in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories. It seeks to provide attractive monthly tax-free income, portfolio diversification and attractive after tax total returns. The fund invests in municipal securities that are exempt from federal income taxes.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.